Additional file 2 of Gp350-targeted CAR-T therapy in EBV-positive Burkitt lymphoma: pre-clinical development of gp350 CAR-T

Supplementary Material 2. Figure S2 gp350-Targeted CAR-T cells with high viability and transduction rates. (A) (F): In the FSC vs SSC scatter plot, the gated cell populations for analysis are shown. The population adjacent to SSC, which was not gated, represents shrunken cells or debris. The gated populations were 72.51% in the CAR-T group and 29.44% in the MOCK-T group. (B) (G): In the FVD-KO vs SSC scatter plot, the gated FVD-negative live cell populations were 92.73% in the CAR-T group and 92.89% in the MOCK-T group. (C) (H): The proportion of CD3-positive T cells was 97.86% in the CAR-T group and 93.79% in the MOCK-T group. (D): The MOCK-T group served as a negative control, with the gating percentage set at 1.73%. (I): Using panel D as the background control, the transduction rate of CAR-T cells was 41.68%. (E) (J): In the CAR-T group, the proportions of CD4+ and CD8+ T cells were 33.02% and 60.61%, respectively. In the MOCK-T group, the proportions of CD4+ and CD8+ T cells were 35.34% and 53.91%, respectively.